Overview

A 105-gene lung cancer panel is a next-generation sequencing assay that reads dozens of clinically relevant genes from a single non-small cell lung cancer (NSCLC) sample. For reference laboratories, distributors, and hospital procurement teams, the decision to adopt or resell such a panel is as much about logistics and quality as about the gene list. This guide frames the sourcing questions that matter most when the assay enters routine clinical volume.

What a 105-Gene Panel Covers

The panel typically spans the pathways that drive and respond to therapy in lung cancer: receptor tyrosine kinase and RAS signaling genes, PI3K-AKT members, cell-cycle regulators, DNA-repair genes, and markers tied to immunotherapy decision-making. Covering more than one hundred genes in one assay lets a single report surface driver mutations, resistance alterations, and eligibility flags for targeted or combination regimens, reducing the need for sequential single-gene tests that consume scarce tissue.

Cold-Chain and Sample Integrity

NGS reagents are temperature sensitive, so the supply chain should protect kits from freeze-thaw and heat during transit. On the sample side, the assay accepts common formats such as formalin-fixed paraffin-embedded tissue and circulating tumor DNA from plasma, but each demands its own pre-analytical handling: prompt fixation for tissue and stabilized collection tubes for plasma. Validated courier routes and clear cold-chain labels keep both reagent and specimen fit for analysis, and a temperature logger on the reagent shipment closes the loop.

Supplier Qualification Checklist

Before committing, buyers should confirm the laboratory's accreditation, the analytical validation behind the 105-gene content, and the turnaround time the workflow realistically supports. Ask for a limits-of-detection statement, a variant-classification policy, and a clearly written report template. A supplier that can demonstrate routine proficiency testing and responsive technical support will protect the downstream clinical value of every order placed and reduce the risk of unreportable failed runs.

Turnaround and Reporting Service Levels

Clinical oncology moves on timelines, so the stated turnaround from sample receipt to signed report should be realistic, not best-case. Buyers should clarify what happens to partial or failed libraries, whether a redraw is offered, and how amendments are communicated. A panel is only as useful as the report that reaches the tumor board, so the format, actionability ranking, and integration with the existing laboratory information system deserve as much scrutiny as the gene list itself.

FAQ

Q: How many genes are assessed by this lung cancer panel? A: The assay is built around 105 genes relevant to lung cancer biology, reported from a single NSCLC sample.

Q: Which sample types can the panel accept? A: Common formats include formalin-fixed paraffin-embedded tissue and plasma-derived circulating tumor DNA, each with its own validated pre-analytical steps.

Q: What should a buyer verify before ordering at volume? A: Laboratory accreditation, the analytical validation package, limits of detection, expected turnaround, and the quality of the delivered report template.